Xconomy

APRIL 14, 2020

Messenger RNA drug developer Arcturus Therapeutics is ready to kick off its first-ever human trials this year, beginning clinical evaluation of its lead drug candidate and testing a vaccine designed to target the novel coronavirus. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 117

Arcturus San Diego Design Develop 117

Xconomy

MAY 3, 2018

In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT ) says it has built a versatile platform for developing a variety of RNA-based medicines. Dueling lawsuits between the ousted CEO and the board could consume. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 49

Arcturus Develop Development San Diego 49

Xconomy

OCTOBER 23, 2017

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.

Arcturus 65

Arcturus San Diego Research Develop 65

Xconomy

MAY 30, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court. No financial terms were disclosed.

Arcturus 56

Arcturus San Diego Develop Development 56

Xconomy

FEBRUARY 2, 2018

Arcturus Therapeutics (NASDAQ: ARCT ) said today it has fired co-founder and CEO Joseph E. Payne (on the right in above photo), and named Mark Herber, vice president of business development and alliance management, as interim president. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

MAY 30, 2017

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.

Arcturus 65

Arcturus San Diego Research Funding 65

Xconomy

FEBRUARY 27, 2018

The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. The San Diego drug developer said late Monday that the typically routine step of ratifying the company’s auditor failed a shareholder vote.

Arcturus 49

Arcturus San Diego Report Develop 49